IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into an additional clinical ...
Ideaya Biosciences enters additional supply pact with Gilead for IDE397
Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...
Frontiers3d
Targeting amino acid metabolism to inhibit gastric cancer progression and promote anti-tumor immunity: a review
Therefore, limiting methionine intake or inhibiting a key enzyme involved in methionine metabolism, MAT2A, is a potential therapeutic approach. However, relevant treatments have not yet been ...